Program
orforglipron
Also written as “Orforglipron”, “LY3502970” and “[14C]-LY3502970”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hypertension · Obesity, Abdominal · Renal Insufficiency, Chronic, led by Eli Lilly.
Drug pageOrforglipron: every studyAll 53 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 5017 open or running | phase 3since Mar 27, 2023 | Apr 25, 2019 | Feb 2027phase 3 · NCT06672549 |
Also a collaborator on its studies: Quotient Sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 28 earlier studies, Apr 25, 2019 to Apr 15, 2024.
- Jan 19, 2023Named orforglipronINNProposed as its International Nonproprietary Name in WHO's List 128 · before, LY3502970
- May 29, 2024Phase 1 study in ObesityNCT06440980 · 533 enrolled · United States
- Sep 3, 2024Phase 3 study in ObesityNCT06584916 · 376 enrolled · United States, Puerto Rico
- Oct 17, 2024Phase 3 study in OverweightNCT06649045 · 712 enrolled · United States, Argentina, Brazil and more
- Nov 1, 20242 phase 3 studies in ObesityNCT06672939, NCT06672549
- Nov 14, 20242 phase 1 studies in HealthyNCT06692348, NCT06704763
- Jan 27, 2025Phase 1 study in ObesityNCT06824051 · 120 enrolled · United States
- Apr 21, 20253 phase 3 studies in HypertensionNCT06952530, NCT06948435, NCT06948422
- May 7, 20253 phase 3 studies in ObesityNCT06993792, NCT06972472, NCT06972459
- Sep 2, 20252 phase 3 studiesNCT07153471, NCT07202884
- Oct 30, 2025Phase 3 study in Peripheral Arterial DiseaseNCT07223593 · 1,205 planned · United States, Argentina, Australia and more
- Nov 17, 2025Phase 3 study in Renal Insufficiency, ChronicNCT07241390 · 7,140 planned · Argentina, Australia, Austria and more
- May 22, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07613307 · 130 planned · India, Saudi Arabia, South Africa and more
- Jun 22, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07668336 · 170 planned · United States, Belgium, Brazil and more
- Aug 25, 20262 phase 3 studiesNCT07790861, NCT07794579
Ahead
- Feb 2027Primary completion: phase 3 study in ObesityNCT06672549
- May 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07613307
- Aug 2027Primary completion: phase 3 study in ObesityNCT06993792
- Aug 2027Primary completion: phase 3 study in ObesityNCT06972472
TargetBeta
“Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist that was approved by the U.S.”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 50 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07794579Overweight · United States, Argentina, China and more | 3 | Recruiting | Aug 2029 | 2,001 |
| NCT07790861Obesity · China | 3 | Not yet recruiting | Mar 2028 | 192 |
| NCT07668336Diabetes Mellitus, Type 2 · United States, Belgium, Brazil and more | 3 | Recruiting | Mar 2030 | 170 |
| NCT07613307Diabetes Mellitus, Type 2 · India, Saudi Arabia, South Africa and more | 3 | Recruiting | May 2027 | 130 |
| NCT07241390Renal Insufficiency, Chronic · Argentina, Australia, Austria and more | 3 | Recruiting | Aug 2031 | 7,140 |
| NCT07223593Peripheral Arterial Disease · United States, Argentina, Australia and more | 3 | Recruiting | Jun 2028 | 1,205 |
| NCT07202884Urinary Incontinence, Stress · United States, Canada, China and more | 3 | Recruiting | Mar 2028 | 1,000 |
| NCT07153471Osteoarthritis · United States, Canada, China and more | 3 | Active, not recruiting | Apr 2028 | 800 |
| NCT06993792Obesity · United States, Argentina, China and more | 3 | Active, not recruiting | Aug 2027 | 1,400 |
| NCT06972472Obesity · United States, Argentina, China and more | 3 | Active, not recruiting | Aug 2027 | 600 |
| NCT06972459Obesity · United States, Argentina, China and more | 3 | Active, not recruiting | Aug 2027 | 800 |
| NCT06952530Hypertension · United States, Argentina, China and more | 3 | Active, not recruiting | Sep 2027 | 487 |
| NCT06948435Hypertension · United States, Argentina, China and more | 3 | Active, not recruiting | Sep 2027 | 487 |
| NCT06948422Hypertension · United States, Argentina, China and more | 3 | Active, not recruiting | Sep 2027 | 974 |
| NCT06824051Obesity · United States | 1 | Completed | Jan 26, 2026 | 120 |
| NCT06704763Healthy · United States | 1 | Completed | Feb 5, 2025 | 27 |
| NCT06692348Healthy · Japan | 1 | Completed | Jun 9, 2025 | 86 |
| NCT06672939Obesity · United States, Israel, Italy and more | 3 | Recruiting | Dec 2027 | 150 |
| NCT06672549Obesity · United States, Belgium, Brazil and more | 3 | Recruiting | Feb 2027 | 125 |
| NCT06649045Overweight · United States, Argentina, Brazil and more | 3 | Completed | Jul 21, 2026 | 712 |
| NCT06584916Obesity · United States, Puerto Rico | 3 | Completed | Nov 21, 2025 | 376 |
| NCT06440980Obesity · United States | 1 | Completed | Jun 2, 2025 | 533 |
| NCT06370728Healthy · United States | 1 | Completed | Jul 23, 2024 | 30 |
| NCT06192108Diabetes Mellitus, Type 2 · United States, China, Germany and more | 3 | Completed | Sep 26, 2025 | 962 |
| NCT06186622Obesity · United States | 1 | Completed | Jul 10, 2024 | 50 |
| NCT06109311Diabetes Mellitus, Type 2 · United States, Brazil, China and more | 3 | Completed | Sep 15, 2025 | 546 |
| NCT06085482Healthy · United States | 1 | Completed | Jan 5, 2024 | 10 |
| NCT06045221Diabetes Mellitus, Type 2 · United States, Argentina, China and more | 3 | Completed | Aug 22, 2025 | 1,698 |
| NCT06023095Overweight · China | 1 | Completed | Jul 29, 2024 | 24 |
| NCT06010004Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Jun 5, 2025 | 401 |
| NCT05971940Diabetes Mellitus, Type 2 · United States, China, India and more | 3 | Completed | Apr 3, 2025 | 559 |
| NCT05936138Renal Insufficiency · United States | 1 | Completed | Apr 11, 2024 | 24 |
| NCT05931380Obesity · Japan | 3 | Completed | Jun 19, 2025 | 238 |
| NCT05882032Hepatic Insufficiency · United States | 1 | Completed | Nov 18, 2024 | 29 |
| NCT05872620Obesity · United States, Argentina, Australia and more | 3 | Completed | Aug 8, 2025 | 1,613 |
| NCT05869903Obesity · United States, Brazil, China and more | 3 | Active, not recruiting | Jul 25, 2025 | 3,127 |
| NCT05841238Obesity · United States | 1 | Completed | Sep 14, 2023 | 52 |
| NCT05803421Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Mar 16, 2026 | 2,749 |
| NCT05573230Healthy · Singapore | 1 | Completed | Jan 17, 2023 | 32 |
| NCT05469126Healthy · Singapore | 1 | Completed | Nov 3, 2022 | 26 |
| NCT05341089Healthy · Singapore | 1 | Completed | Sep 1, 2022 | 39 |
| NCT05313802Obesity · United States | 1 | Completed | Sep 9, 2022 | 72 |
| NCT05110794Healthy · Singapore | 1 | Completed | Feb 10, 2022 | 34 |
| NCT05086445Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Sep 5, 2022 | 62 |
| NCT05051579Obesity · United States, Canada, Hungary and more | 2 | Completed | Aug 25, 2022 | 272 |
| NCT05051566Healthy · United Kingdom | 1 | Completed | Apr 4, 2022 | 26 |
| NCT05048719Diabetes Mellitus, Type 2 · United States, Hungary, Poland and more | 2 | Completed | Sep 30, 2022 | 383 |
| NCT04680767Healthy · United Kingdom | 1 | Completed | Jul 3, 2021 | 6 |
| NCT04426474Diabetes Mellitus, Type 2 · United States, Germany | 1 | Completed | Jul 12, 2021 | 68 |
| NCT03929744Healthy · United States | 1 | Completed | Nov 2, 2020 | 133 |
How it is read
Names in the registry
- “Orforglipron”, 33 entries
- “LY3502970”, 16 entries
- “[14C]-LY3502970”, 1 entry
- “[¹⁴C]-LY3502970”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 18 studies
- Diabetes Mellitus, Type 2, 11 studies
- Hypertension, 3 studies
- Obesity, Abdominal, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.